The mammalian core clock genes, Periods (Per1 and Per2), have tumor suppressor properties. Decreased expression of Per1 and Per2 has been reported in several types of human cancers. On the other hand, overexpression of Per1 or Per2 inhibits cancer cell growth in culture. The authors have shown that downregulation of Per1 or Per2 enhances cancer growth in vitro. These genes also regulate the amount of cell proliferation-related molecules, many of which are therapeutic targets. In animals, tumors grow with clear circadian organization, and Per1 and Per2 exert their tumor suppressor functions in a circadian time-dependent manner. Downregulation of Per1 or Per2 increases tumor growth only at certain specific times of the day. Per1 and Per2 differentially regulate tumor growth rhythm in vivo. These data suggest that the therapeutic efficacy of antiproliferation agents depends on the time of day of drug delivery. The optimal times of day may be shifted in tumors that have mutant Period genes.
Introduction
Circadian organization is universally conserved and controlled by a set of core circadian clock genes. Although the components of the circadian clock are different among species, the underlying mechanisms are similar: using transcriptional-translational negative feedback loops to generate oscillations of core clock gene expression with a near 24-hour period. [1] [2] [3] In mammals, the rhythmic expression of Period genes (Per1, Per2) is essential for creating a beating clock. Increasing evidence supports the importance of the circadian clock for the organisms' well-being, and circadian disruption is a cancer risk factor. 4 Although the molecular links bet ween the circadian clock and cancer are not yet clear, connections between the circadian clock and cell cycle clock have been clearly and repeatedly demonstrated. In translucent zebrafish, the daily DNA replication peak occurs during the end of the day. 5 Mouse liver regeneration experiments demonstrate that the circadian clock tightly gates the entry of liver cells into mitosis. 6 In human beings, the expression of cell cycle regulators demonstrates circadian organization in most investigated tissues. The activity of thymidylate synthase, a DNA synthesis marker, peaks in the early afternoon in human oral mucosa, gut epithelium, bone marrow, and skin. [7] [8] [9] Deregulated cell cycle progression is a hallmark of cancer. Disrupted circadian organization is one important cause of cell cycle deregulation.
The cancer-prone phenotype of mice with homozygous Per2 mutation has prompted studies on the role of circadian clock genes on cell cycle control and tumorigenesis. 10 Diminished expression levels of Per1 and Per2 mRNA have been reported in human colorectal cancer samples. 11, 12 Mutation of these 2 core clock genes has also been identified in breast and colorectal cancers. 13 On the other hand, overexpression of Per1 or Per2 inhibits cancer cell growth in culture as well as in animals. [14] [15] [16] [17] [18] In this study, we downregulated the expression of Per1, Per2, or both in a mouse breast cancer model and examined their effects on tumor growth and its circadian organization. We document that the tumor growth in vivo is highly circadian clock coordinated. 19 Depletion of PER1 or PER2 enhances tumor growth rate at certain times of the day by differentially altering gene-specific circadian tumor growth rhythms.
Chronotherapy, an optimal circadian time-dependent anticancer drug delivery method, can enhance tumor response while simultaneously reducing toxic side effects to the host. This has been repeatedly demonstrated in human beings with ovarian, colorectal, and kidney cancers. [20] [21] [22] [23] Chronotherapy, however, has failed to become a routine medical oncology practice. Determining the mechanisms by which the clock coordinates the toxic-therapeutic index of cytotoxic drugs as well as potential clock gene-based novel therapeutics should support the application of chronotherapy more broadly for human cancer. 
Materials and Methods

Animals and Housing Conditions
Cell Culture, siRNA Transfection and In Vitro Growth
MTCL mouse breast cancer cells were grown in RPMI 1640 with 10% fetal bovine serum at 37°C. For siRNA transfection, 100 to 200 pmol of siRNA oligo targeting Green Fluorescent Protein (GFP) (control), Per1 or Per2 was transfected into cells by 5 mL of Lipofectimine 2000 in a 6-well plate. After 72 hours of siRNA transfection, cells were lysed by NP40 buffer to obtain total cellular extracts for Western blot. To determine cell growth rate in culture, 48 hours after siRNA treatment, cells were replated in a 96-well plate, and cell number was determined daily by MTT assay. 19 
Establishment of Per1 or Per2 Downregulated Cells
A retrovirus-mediated shRNA expression system was used to stably downregulate Per1 or Per2. 19 The shRNA sequences were the same sequences as siRNA that target GFP, Per1, or Per2. The retroviruses were produced in a PT67 retroviral packaging cell line (Clontech, Mountain View, CA). Two days after virus infection, 1 mg/mL of puromycin was added to the medium to select cells with retrovirus integrated into their genomes. The downregulation efficiency was examined after 3 weeks of puromycin selection.
Tumor Growth In Vivo
Four types of cells MTCL cell line expressing, control shRNA, Per1 shRNA, Per2 shRNA, and Per1/Per2 shRNA were injected under the back skin of C3H mice (2 × 10 4 cells/mouse). Each type of MTCL cell was inoculated into 27 mice, which were divided into 3 groups, housed under 3 light-dark schedules. After 7 to 8 days of inoculation, the size of each tumor was measured twice a day with a 12-hour interval. Therefore, the size of each type of MTCL tumor was measured 6 times within each day (HALO 2, 6, 10, 14, 18, and 22). The daily tumor growth rates were calculated as described. 19, 24 For example, the tumor size (TS) difference between HALO 14 and 2, DTS = TS(14) -TS (2), is defined as the daily tumor growth rate at the circadian midpoint, HALO 8. Overall, each type of MTCL tumor has tumor growth rate at 6 circadian times at HALO 4, 8, 12, 16, 20 , and 24.
Data Analysis
To determine tumor growth rhythm, a cosine curve fit was tested by Chronolab v4.6 (Bioengineering & Chronobiology Laboratory, Pontevedra, Spain) for statistical significance. Cosine curves with 24-hour and 12-hour fits were evaluated for each type of tumor growth. ANOVA (repeated measures analysis of variance) was performed to compare tumor growth rates at each of 6 circadian times, and overall daily TSs were compared by unpaired t tests where significance was determined (P < .05, SPSS, SAS software).
Results
Downregulation of Per1 or Per2 Increases Cancer Cell Growth In Vitro
There are several reports that overexpression of Per1 or Per2 inhibits cancer cell growth in culture. [14] [15] [16] [17] [18] We have shown that downregulation of Per2 in both mouse breast cancer cell and human colorectal cancer cells enhances cell growth. 25 In MTCL mouse breast cancer cells, downregulation of Per1 or Per2 increases cyclin D1 and Cox-1 protein levels. The cyclin E protein is also slightly increased ( Figure  1A ). It has been shown that in HCT116 human colorectal cancer cells, overexpression of Per1 reduces C-Myc protein levels. 15 We have noticed that alteration of C-Myc expression by Per1 or Per2 is cell-line dependent. In the human colorectal cancer cell line, SW480, the level of C-Myc is increased after Per2 is downregulated by siRNA (data not shown). In MTCL mouse breast cancer cells, downregulation of Per1 or Per2 does not alter C-Myc protein levels. Cox-1 is constitutively expressed in most tissues. Blocking Cox-1 expression slows tumor growth. 26 Downregulation of Per1 or Per2 increases cell growth in vitro ( Figure 1B ). This may be partly because of the increased expression of cyclin D1, cyclin E, and Cox-1. Although downregulation of Per1 or Per2 elevates cyclin D, cyclin E, and Cox-1 to similar degrees in this experiment, it seems downregulation of Per2 has a stronger effect on cell growth.
Downregulation of Per1 or Per2 Enhances Tumor Growth In Vivo
To determine the effect of PER1 and PER2 on cancer cell growth in vivo, we transplanted MTCL mouse breast cancer cells into syngeneic C3H mice and measured TSs. First, we established stable MTCL cell lines with Per1 or Per2 downregulated by shRNA. 19 The tumors became measurable after 7 days of inoculation in mice. Downregulation of Per1 or Per2 does not alter this lag time. Tumors with downregulated Per1 or Per2 grow faster than the control tumors on average ( Figure 2 ). Control tumor growth rate is 85.9 ± 7.2 mm 3 /d. The growth rate of Per1 downregulated tumors is 111.8 ± 9.3 mm 3 /d (P < .05). The growth rate of Per2 downregulated tumors is 127.8 ± 16.8 mm 3 /d (P < .01). It seems tumors with downregulated Per2 also grow faster than tumors with downregulated Per1, even though the difference is not statistically significant (P = .46).
Tumor Growth In Vivo Is Time Dependent
The expressions of Per1 and Per2 have robust circadian rhythms at both RNA and protein levels. If the presence of PER1 or PER2 proteins inhibits tumor growth, then one would expect that PER1 and PER2 exert their tumor suppression function only at certain times of the day and not at others.
To determine whether this is the case, we measured the TS at 6 circadian times within each day. The TSs of all 3 types of MTCL tumors vary substantially within each day. However, the size of the control tumor and that of tumors with Per1 or Per2 downregulated peak at different times of the day ( Figure  3A) . Therefore, if the TSs are measured only once a day, one might never detect the enhanced tumor growth by Per1 or Per2 downregulation. If tumors are measured near the end of the light phase or near the end of the dark phase, it is found that all 3 types of tumors grow at the same rate ( Figure 3B ).
Per1 and Per2 Modulate Circadian-Gated Tumor Growth Rhythm In Vivo
To obtain the circadian pattern of tumor growth, we converted 6-time-point TSs into a growth rhythm. The growth rate of the control tumor had 2 daily peaks: a major one in the middle of the night and a minor one in the middle of the day. Downregulation of Per1 does not significantly alter the phase of the tumor growth rhythm but enhances the amplitude ( Figure 4A ). Downregulation of Per2, however, dramatically alters both the phase and amplitude of the tumor growth rhythm ( Figure 4A ).
We have also partially downregulated both Per1 and Per2 in MTCL cells by shRNA. However, the efficiency of the double knockdown was low. We determined the knockdown efficiency of Per1 and Per2 by real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) measurements of their RNA levels. Both of them were downregulated about 30% each (data not shown). Nevertheless, MTCL tumors treated with Per1 and Per2 double shRNA tend to display 1 growth peak within each day, whereas the other 3 types of tumors demonstrate a 2-peak daily rhythm. ( Figure 4B and Table 1 ).
Discussion
Disruption of the circadian clock increases the incidence of breast, colon, prostate, and endometrial cancers. [27] [28] [29] Although the molecular mechanisms are not clear, the link between clock disruption and cancer is not surprising. Some 10% of all mouse gene transcriptions in tissues are expressed with circadian rhythmicity. 30 At the protein level, 20% of all proteins appear to display daily oscillations. 31 Therefore, deregulation of the clock, per se, damages the temporal organization of these gene and protein expressions, leading to the deregulated cell proliferation and subsequent tumorigenesis. It is also possible that these clock genes have nonclock functions, which also regulate cell cycle progression, DNA damage response, and genomic stability directly. One example of a clock gene with nonclock function is Bmal1, which is also essential for bone and joint homeostasis. 32 Likewise, PER and CRY proteins may independently affect tumorigenesis. In the circadian clockwork, PER and CRY proteins are partners. They form complexes to suppress CLOCK/BMAL1-mediated transcription. However, knockout of Per2 and Cry1/2 have different effects. Per2 knockout promotes cancer development, whereas Cry1/2 knockout in p53 -deficient mice delays cancer development. 25, 33 Among all clock gene knockout animals, the cancerprone phenotype has been reported uniquely in Per2 knockout mice. Although the cancer prone phenotype has not been reported in Per1 knockout mice, the phenotype is enhanced in Per1/Per2 double knockout mice. 34 We have downregulated Per1 and Per2 expression in several types of cancer cells. 19, 25 Uniformly, this manipulation increases cell growth rate in vitro and in vivo. It seems that downregulation of Per2 has a more potent effect on cell growth than does downregulation of Per1. This may be because the knockdown efficiencies are different or, more likely, because PER1 and PER2 differentially regulate specific gene expressions. Although in our data, downregulation of Per1 and Per2 increases the levels of cyclin D, cyclin E, and Cox-1 to the same degree, it is unknown how PER1 and PER2 regulate the expression of other proliferation-related genes. Per1 and Per2 share sequence homology, and their knockout mice display similar behavioral phenotypes. However, at the molecular level, PER1 and PER2 differentially regulate the expression of other clock genes. 35, 36 It would be of interest to compare the gene expression of Per1 knockout and Per2 knockout mice by micro array and protein array.
Studies have found mutant clock genes or altered clock gene expression in several cancers. The results of these findings sometimes appear contradictory. Most of these studies compare clock gene expression by real-time RT-PCR in tumor samples and adjacent normal tissue samples collected at 1 time of the day. Depending on the time of day when these samples are collected, these results might be misleading. We have compared the core clock gene expressions in the transplanted tumor and in the liver of those tumorbearing mice. The circadian rhythm of Per1, Per2, and Rev-erba is shifted in the tumor compared with the liver, and the amplitudes of all clock gene rhythms are damped. Therefore, comparing tumor sample and normal tissue samples at 1 time point will not reveal whether the overall levels of these clock genes in the tumor are lower or higher.
The oscillation of tumor growth rate also raises a potential pitfall of measuring tumor growth in vivo. The enhanced tumor growth after Per1 or Per2 downregulation can be easily missed if the TSs are measured only once or at the wrong time of day. It is unclear why the TS waxes and wanes so dramatically within each day. This 2-peak tumor growth rhythm is correlated with the rhythms of cyclin D and C-Myc in the tumor, indicating that proliferation molecules are waxing and waning twice each day. Whether there is a simple cause-effect relationship between these gene expressions and the tumor growth rate is not known. It seems that this 2-peak rhythm is not unique to the tumor. The expression of cyclin E and thymidylate synthase as well as thymidylate synthase activity and S-phase fraction all demonstrate 2-peak daily rhythms in the bone marrow. 37 The mechanisms that generate this 12-hour rhythm are not clear. We speculate that this 12-hour rhythm is the result of balancing the temporal organizing effects of 2 circadian clocks-the local tumor cell clock and the systemic, host clock. In the case of tumor growth, tumor growth rate may be modulated by the amount of PER1 and PER2 proteins within the tumor as well as the circadian signals from the host (hormones, growth factors, etc). If there is a timing difference between the rhythm of host signals and the rhythm of tumor Per1/2 gene expression, this could explain these 2 daily peaks in tumor growth rate. The delayed peak expression of tumor Per1, Per2, and Rev-erba suggests that the tumor clock peaks several hours later than the host clock. Downregulation of tumor cell Per1 or Per2 could then shift the overall tumor PER protein expression pattern, which causes the shift in tumor growth rhythm. Because the expression patterns of Per1 and Per2 are slightly different from one another, downregulation of Per1 and Per2 would differentially shift the tumor growth rhythm. When both Per1 and Per2 are downregulated 100% in the tumor, we might then predict that the resultant tumor growth rhythm would be solely controlled by the circadian signal from the host. We plan to alter Per1 and Per2 expression in both tumor and host to examine tumor growth rhythms and to determine the relative impacts of the tumor cell clock and host clock on cancer growth.
The tumor suppression properties of Per1/2 genes raises the possibility of using Per1/2 gene products as anticancer drug targets. Simply constitutively increasing PER protein levels may not, however, be able to prevent cancer, as rhythmic PER1 or PER2 expression is essential for a beating clock; overexpression of PER1 or PER2 may lead to a disrupted clock and, paradoxically, high cancer risk. 38, 39 It is unclear whether the clock function and tumor suppression function of PER proteins can be separated. If these 2 functions reside at separate domains of the PER proteins, then it is possible, in principle, to enhance the tumor suppression functions of PER without affecting their clock functions.
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